摘要
目的 探讨促肝细胞生长素对重型肝炎的疗效及安全性。方法 选择急性、亚急性和慢性重型肝炎患者 3 5 8例 ,静脉滴注促肝细胞生长素 ,观察患者的症状、ALT、AST、PTA等项目 ,并判断药物治疗的疗效。结果 重型肝炎患者应用促肝细胞生长素后其乏力明显缓解 ,ALT、AST、TBIL下降 ,ALB及PTA明显升高 ,与治疗前比较 ,差异有非常显著性 (P <0 .0 0 1)。对生存 2周以上的急性重型肝炎、亚急性重型肝炎及慢性重型肝炎患者总有效率分别为 78.4%、88.9%及2 7.5 %。结论 促肝细胞生长素可以用于治疗重型肝炎。
Objective To investigate the effect and safety of intravenation of hepatocyte growth promoting factors on hepatitis gravis.Methods 358 cases with hepatitis gravis were employed in the clinical research. The levels of ALT, AST and PTA were measured before and after treatment with intravenation of hepatocyte growth promoting factors.Results After the treatment of hepatocyte growth promoting factors the levels of ALT,AST and TBIL were decreased; the levels of ALB and PTA were increased. The effective rate was 78.4% on hepatitis gravis. The effective rates on acute, subacute and chronic hepatitis were 78.4%,84.8% and 27.5%, respectively.Conclusion Hepatocyte growth promoting factors is effective on hepatitis gravis.
出处
《临床内科杂志》
CAS
北大核心
2002年第4期255-257,共3页
Journal of Clinical Internal Medicine
